Ota Fuchs

Institute of Hematology and Blood Transfusion

Ota Fuchs graduated from the Chemical Technological University, Prague, Czech Republic in 1971. He obtained his PhD in Biochemistry from the Faculty of Natural Sciences, Charles University, Prague in 1981. He is currently employed as a Senior Scientist at the Institute of Hematology and Blood Transfusion, Prague. He has undertaken, as a visiting scientist, short-term affiliations in the Beatson Institute for Cancer Research, Glasgow, UK; Institute of Experimental Medicine of the Russian Academy of Medical Sciences in St Peterburg, Russia; and in the Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada. He was principal investigator of five projects for the Internal Grant Agency of Ministry of Health of Czech Republic and of one grant project for the Grant Agency of Czech Republic.

3books edited

5chapters authored

Latest work with IntechOpen by Ota Fuchs

This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML.

Go to the book